260 related articles for article (PubMed ID: 25052037)
1. Risk of hemorrhage in patients with chronic liver disease and coagulopathy receiving pharmacologic venous thromboembolism prophylaxis.
Reichert JA; Hlavinka PF; Stolzfus JC
Pharmacotherapy; 2014 Oct; 34(10):1043-9. PubMed ID: 25052037
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of venous thromboembolism prophylaxis in patients with chronic liver disease.
Smith CB; Hurdle AC; Kemp LO; Sands C; Twilla JD
J Hosp Med; 2013 Oct; 8(10):569-73. PubMed ID: 24101541
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of pharmacologic prophylaxis for venous thromboembolism in patients with chronic liver disease.
Barclay SM; Jeffres MN; Nguyen K; Nguyen T
Pharmacotherapy; 2013 Apr; 33(4):375-82. PubMed ID: 23553808
[TBL] [Abstract][Full Text] [Related]
4. Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
Reeves D; Liu CY
J Oncol Pharm Pract; 2010 Mar; 16(1):27-31. PubMed ID: 19401307
[TBL] [Abstract][Full Text] [Related]
5. Enoxaparin versus tinzaparin for venous thromboembolic prophylaxis during rehabilitation after acute spinal cord injury: a retrospective cohort study comparing safety and efficacy.
Marciniak CM; Kaplan J; Welty L; Chen D
PM R; 2012 Jan; 4(1):11-7. PubMed ID: 22269449
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Cohort Analysis of Pharmacologic VTE Prophylaxis and Padua Prediction Score in Hospitalized Patients With Chronic Liver Disease.
Moorehead KJ; Jeffres MN; Mueller SW
J Pharm Pract; 2017 Feb; 30(1):58-63. PubMed ID: 26475125
[TBL] [Abstract][Full Text] [Related]
7. Risk of venous thromboembolism in patients with chronic liver disease and the utility of venous thromboembolism prophylaxis.
Pincus KJ; Tata AL; Watson K
Ann Pharmacother; 2012 Jun; 46(6):873-8. PubMed ID: 22570429
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
9. Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study.
Kwiatt ME; Patel MS; Ross SE; Lachant MT; MacNew HG; Ochsner MG; Norwood SH; Speier L; Kozar R; Gerber JA; Rowell S; Krishnakumar S; Livingston DH; Manis G; Haan JM
J Trauma Acute Care Surg; 2012 Sep; 73(3):625-8. PubMed ID: 22929493
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis against venous thromboembolism in hospitalized medically ill patients.
Pendergraft T; Liu X; Edelsberg J; Phatak H; Vera-Llonch M; Liu LZ; Oster G
Circ Cardiovasc Qual Outcomes; 2013 Jan; 6(1):75-82. PubMed ID: 23300270
[TBL] [Abstract][Full Text] [Related]
12. Suboptimal use of pharmacological venous thromboembolism prophylaxis in cirrhotic patients.
Yang LS; Alukaidey S; Croucher K; Dowling D
Intern Med J; 2018 Sep; 48(9):1056-1063. PubMed ID: 29468795
[TBL] [Abstract][Full Text] [Related]
13. Risk factors and pharmacologic prophylaxis for venous thromboembolism in elective spine surgery.
McLynn RP; Diaz-Collado PJ; Ottesen TD; Ondeck NT; Cui JJ; Bovonratwet P; Shultz BN; Grauer JN
Spine J; 2018 Jun; 18(6):970-978. PubMed ID: 29056565
[TBL] [Abstract][Full Text] [Related]
14. Safety of venous thromboembolism prophylaxis with fondaparinux in ischemic stroke.
Hackett CT; Ramanathan RS; Malhotra K; Quigley MR; Kelly KM; Tian M; Protetch J; Wong C; Wright DG; Tayal AH
Thromb Res; 2015 Feb; 135(2):249-54. PubMed ID: 25554497
[TBL] [Abstract][Full Text] [Related]
15. Risk-assessment and pharmacological prophylaxis of venous thromboembolism in hospitalized patients with chronic liver disease.
Bogari H; Patanwala AE; Cosgrove R; Katz M
Thromb Res; 2014 Dec; 134(6):1220-3. PubMed ID: 25294587
[TBL] [Abstract][Full Text] [Related]
16. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease.
Dabbagh O; Oza A; Prakash S; Sunna R; Saettele TM
Chest; 2010 May; 137(5):1145-9. PubMed ID: 20040609
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients. A retrospective multicenter study.
Nieto JA; Cámara T; Camacho I;
Eur J Intern Med; 2014 Oct; 25(8):717-23. PubMed ID: 25091470
[TBL] [Abstract][Full Text] [Related]
18. A retrospective analysis of the effectiveness of low molecular weight heparin for venous thromboembolism prophylaxis in trauma patients.
Gritsiouk Y; Hegsted DA; Schlesinger P; Gardiner SK; Gubler KD
Am J Surg; 2014 May; 207(5):648-51; discussion 651-2. PubMed ID: 24560359
[TBL] [Abstract][Full Text] [Related]
19. Identification of residual risk factors for the development of venous thromboembolism in medical inpatients receiving subcutaneous heparin therapy for prophylaxis.
Kato S; Shimada YJ; Friedmann P; Kashan G; Husk G; Bergmann SR
Coron Artery Dis; 2012 Jun; 23(4):294-7. PubMed ID: 22421548
[TBL] [Abstract][Full Text] [Related]
20. Should patients with chronic liver disease receive venous thromboembolism prophylaxis?
Dang JD; Davis LE
JAAPA; 2015 Jun; 28(6):27-8, 30. PubMed ID: 25989432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
